Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.010
+0.040 (4.10%)
Jun 26, 2025, 12:44 PM - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $4.37M in the quarter ending March 31, 2025, with 155.41% growth. This brings the company's revenue in the last twelve months to $13.65M, down -28.19% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$13.65M
Revenue Growth
-28.19%
P/S Ratio
2.07
Revenue / Employee
$758,389
Employees
18
Market Cap
60.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IRD News
- 5 hours ago - Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 3 days ago - Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program - GlobeNewsWire
- 24 days ago - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewsWire
- 7 weeks ago - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - GlobeNewsWire
- 2 months ago - Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - GlobeNewsWire